CHICAGO—Findings from a Phase III trial show that initial single-agent therapy with a new oral drug called afatinib prolongs progression- free survival in patients with advanced lung adenocarcinomas that harbour EGFR mutations, compared with current standard treatment. Afatinib broadly blocks …
ASCO
CHICAGO—At the Plenary Session of ASCO Maha Hussain MD, FACP of the University of Michigan in Ann Arbor presented results from a long-term, multicenter Phase III international clinical trial comparing two common therapies for men with hormone-sensitive metastatic prostate cancer. …
Volker Diehl
George Canellos
Hodgkin’s Disease: 10-Year Results Show Further Benefit From Escalated BEACOPP Therapy
REFERENCE: Abstract 8015, ASCO Annual Meeting Chicago June 1-5, 2007
VOLKER DIEHL, University of Cologne
GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston
Long-term results presented at
VOLKER DIEHL, University of Cologne
GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston
Long-term results presented at
…
Christian Manegold
Roy Herbst
More Support for Bevacizumab in Advanced Lung Cancer
REFERENCE: Abstract LBA7514, ASCO Annual Meeting Chicago June 1-5, 2007
CHRISTIAN MANEGOLD, Heidelberg University, Mannheim
COMMENT: ROY HERBST, MD Anderson Cancer Center, Houston
The benefit of adding bevacizumab
CHRISTIAN MANEGOLD, Heidelberg University, Mannheim
COMMENT: ROY HERBST, MD Anderson Cancer Center, Houston
The benefit of adding bevacizumab
…
Christiane Kuhl
Julie Gralow
MRI Better Than Mammography for Detecting High-Grade Ductal Carcinoma In Situ?
REFERENCE: 1504, ASCO Annual Meeting Chicago June 1-5, 2007
CHRISTIANE KUHL, University of Bonn, Germany
COMMENT: JULIE GRALOW, University of Washington, Seattle
The ASCO meeting
CHRISTIANE KUHL, University of Bonn, Germany
COMMENT: JULIE GRALOW, University of Washington, Seattle
The ASCO meeting
…
Aimery de Gramont
Robert Mayer
MOSAIC Study Six Year Results: Adjuvant Oxaliplatin Adds Survival Advantage for Patients with Stage III Colorectal Cancer
REFERENCE: 4007, ASCO Annual Meeting Chicago June 1-5, 2007
AIMERY DE GRAMONT, St Antoine Hospital, Paris
COMMENT: ROBERT
AIMERY DE GRAMONT, St Antoine Hospital, Paris
COMMENT: ROBERT
…
Josep Llovet
Robert Mayer
Sorafenib The ‘New Standard’ for Advanced Liver Cancer
REFERENCE: ABSTRACT 5 (Plenary Session), ASCO Annual Meeting Chicago June 1-5, 2007
JOSEP LLOVET, IDIBAPS Hospital Clinic, Barcelona, and Mount Sinai School of Medicine, New York
COMMENT: ROBERT
JOSEP LLOVET, IDIBAPS Hospital Clinic, Barcelona, and Mount Sinai School of Medicine, New York
COMMENT: ROBERT
…
Bernard Escudier
Dean Bajorin
Bevacizumab in Advanced Kidney Cancer: Another Treatment Gives Benefit in First Line
REFERENCE: ABSTRACT 3, ASCO Annual Meeting Chicago June 1-5, 2007
BERNARD ESCUDIER, Gustave Roussy Institute, Villejuif
COMMENT: DEAN BAJORIN, Memorial Sloan-Kettering Cancer Center, New
BERNARD ESCUDIER, Gustave Roussy Institute, Villejuif
COMMENT: DEAN BAJORIN, Memorial Sloan-Kettering Cancer Center, New
…
Ben Slotman
Roy Herbst
Prophylactic Cranial Irradiation: Fewer Brain Metastases, Longer Survival for Patients with Small Cell Lung Cancer
REFERENCE: ABSTRACT 4, ASCO Annual Meeting Chicago June 1-5, 2007
BEN SLOTMAN, VU Medical Center, Amsterdam
COMMENT: ROY HERBST, MD Anderson
BEN SLOTMAN, VU Medical Center, Amsterdam
COMMENT: ROY HERBST, MD Anderson
…
Lawrence Wickerham
Invasive Breast Cancer Chemoprevention Trials Assessed
REFERENCE: ABSTRACT Special Session; American Association for Cancer Research Centennial Meeting, April 14-18, Los Angeles
LAWRENCE WICKERHAM, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh
The best options for preventing invasive breast
LAWRENCE WICKERHAM, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh
The best options for preventing invasive breast
…
Alberto Sobrero
Cetuximab With Irinotecan: Phase III Study Shows Benefit in Patients with Oxaliplatin-Refractory Colorectal Cancer
REFERENCE: ABSTRACT LB-2; AACR 2007, Los Angeles, Plenary Session
ALBERTO SOBRERO, Ospedale San Martino, Genoa
Cetuximab could become a mainstay of treatment for colorectal
ALBERTO SOBRERO, Ospedale San Martino, Genoa
Cetuximab could become a mainstay of treatment for colorectal
…
Fritz Schröder
Opportunistic Prostate Screening May Not Save Lives!
REFERENCE: AACR 2007, Los Angeles
FRITZ SCHRÖDER, Erasmus University, Rotterdam
Though elective screening appears to have reduced the number of patients who die from prostate cancer in the United States, this
FRITZ SCHRÖDER, Erasmus University, Rotterdam
Though elective screening appears to have reduced the number of patients who die from prostate cancer in the United States, this
…